These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 15453953

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.
    Pawson R, Dyer MJ, Barge R, Matutes E, Thornton PD, Emmett E, Kluin-Nelemans JC, Fibbe WE, Willemze R, Catovsky D.
    J Clin Oncol; 1997 Jul; 15(7):2667-72. PubMed ID: 9215839
    [Abstract] [Full Text] [Related]

  • 4. The role of alemtuzumab in the management of T-cell malignancies.
    Dearden C.
    Semin Oncol; 2006 Apr; 33(2 Suppl 5):S44-52. PubMed ID: 16720203
    [Abstract] [Full Text] [Related]

  • 5. Alemtuzumab in T-cell malignancies.
    Dearden CE, Matutes E, Catovsky D.
    Med Oncol; 2002 Apr; 19 Suppl():S27-32. PubMed ID: 12180489
    [Abstract] [Full Text] [Related]

  • 6. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.
    Pangalis GA, Dimopoulou MN, Angelopoulou MK, Tsekouras C, Vassilakopoulos TP, Vaiopoulos G, Siakantaris MP.
    Med Oncol; 2001 Apr; 18(2):99-107. PubMed ID: 11778765
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Alemtuzumab.
    Ravandi F, O'Brien S.
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):39-51. PubMed ID: 15757437
    [Abstract] [Full Text] [Related]

  • 9. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
    McCune SL, Gockerman JP, Moore JO, Decastro CM, Bass AJ, Chao NJ, Long GD, Vredenburgh JJ, Gasparetto C, Adams D, Payne N, Rizzieri DA.
    Leuk Lymphoma; 2002 May; 43(5):1007-11. PubMed ID: 12148879
    [Abstract] [Full Text] [Related]

  • 10. Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).
    Gautschi O, Blumenthal N, Streit M, Solenthaler M, Hunziker T, Zenhäusern R.
    Eur J Haematol; 2004 Jan; 72(1):61-3. PubMed ID: 14962265
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Alemtuzumab in CLL and other lymphoid neoplasms.
    Ravandi F, O'brien S.
    Cancer Invest; 2006 Nov; 24(7):718-25. PubMed ID: 17118783
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.
    Querfeld C, Mehta N, Rosen ST, Guitart J, Rademaker A, Gerami P, Kuzel TM.
    Leuk Lymphoma; 2009 Dec; 50(12):1969-76. PubMed ID: 19860617
    [Abstract] [Full Text] [Related]

  • 15. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.
    Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, Catovsky D.
    Leuk Res; 1998 Feb; 22(2):185-91. PubMed ID: 9593475
    [Abstract] [Full Text] [Related]

  • 16. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.
    Keating MJ, Cazin B, Coutré S, Birhiray R, Kovacsovics T, Langer W, Leber B, Maughan T, Rai K, Tjønnfjord G, Bekradda M, Itzhaki M, Hérait P.
    J Clin Oncol; 2002 Jan 01; 20(1):205-13. PubMed ID: 11773171
    [Abstract] [Full Text] [Related]

  • 17. [Treatment of T-cell prolymphocytic leukemia with monoclonal anti- CD52 antibody (alemtuzumab].
    Fløisand Y, Brinch L, Gedde-Dahl T, Tjønnfjord GE.
    Tidsskr Nor Laegeforen; 2004 Mar 18; 124(6):768-70. PubMed ID: 15039804
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
    Osuji N, Del Giudice I, Matutes E, Morilla A, Owusu-Ankomah K, Morilla R, Dunlop A, Catovksy D.
    Leuk Lymphoma; 2005 May 18; 46(5):723-7. PubMed ID: 16019510
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.